BIOSOLVE-I
36-month results

Conclusions
- Excellent long-term outcomes at 3 years with a low Target Lesion Failure (TLF) rate and no cardiac death or scaffold thrombosis
- No TLF events were observed after the first year

Study design
Prospective, multi-center, First-In-Man trial testing DREAMS (Drug-Eluting Absorbable Magnesium Scaffold) in 46 patients with a total of 47 de novo lesions

Principal investigator
- Prof. Michael Haude, Neuss, Germany

Endpoints
Primary endpoint
- TLF defined as a composite of cardiac death, Target-Vessel Myocardial Infarction (TV-MI) and clinically driven Target Lesion Revascularization (cd-TLR) at 6 and 12 months

Secondary endpoints (selected)
- Late Lumen Loss (LLL) at 6 and 12 months
- Scaffold thrombosis at 1, 24 and 36 months
- Cumulative rates of TLF at 1, 24 and 36 months



BIOTRONIK
excellence for life

Clinical results



* TLF defined as a composite of cardiac death, target-vessel MI and cd-TLR

Events at 36 months [in %]	BIOSOLVE-I n = 46
TLF	6.8
Cardiac death	0.0
Target-vessel MI	2.3
cd-TLR	4.5
Definite/probable scaffold thrombosis	0.0

BIOTRONIK AG
Ackerstrasse 6
8180 Bülach · Switzerland
Tel +41 (0) 44 8645111
Fax +41 (0) 44 8645005
info.vi@biotronik.com
www.biotronik.com

BIOTRONIK
excellence for life